[Migraine: a disease, not a symptom].
Henry
Patrick
P
Département de neurologie Hôpital Pellegrin 33076 Bordeaux. patrick.henry@chu-bordeaux.fr
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001262:Atenolol / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004087:Dihydroergotamine / Q000627:therapeutic use; D005444:Flunarizine / Q000627:therapeutic use; D018682:GABA Agents / Q000627:therapeutic use; D006801:Humans; D007217:Indoramin / Q000627:therapeutic use; D008784:Methysergide / Q000627:therapeutic use; D008881:Migraine Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D023303:Oxazolidinones / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D014363:Tryptamines; D014635:Valproic Acid / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D018712:Analgesics, Non-Narcotic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018682:GABA Agents; D023303:Oxazolidinones; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D007217:Indoramin; C089750:zolmitriptan; D004087:Dihydroergotamine; D001262:Atenolol; D014635:Valproic Acid; D005444:Flunarizine; D008784:Methysergide